Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial

F. McDonald*, G. G. Hanna

*Corresponding author for this work

Research output: Contribution to journalEditorial

7 Citations (Scopus)
Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalClinical Oncology
Volume30
Issue number1
Early online date16 Nov 2017
DOIs
Publication statusPublished - Jan 2018

Cite this

@article{2c9b4844395c42c8be5d0808129965be,
title = "Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial",
author = "F. McDonald and Hanna, {G. G.}",
year = "2018",
month = "1",
doi = "10.1016/j.clon.2017.10.013",
language = "English",
volume = "30",
pages = "1--4",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "Elsevier",
number = "1",

}

Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial. / McDonald, F.; Hanna, G. G.

In: Clinical Oncology, Vol. 30, No. 1, 01.2018, p. 1-4.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial

AU - McDonald, F.

AU - Hanna, G. G.

PY - 2018/1

Y1 - 2018/1

UR - http://www.scopus.com/inward/record.url?scp=85034456360&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2017.10.013

DO - 10.1016/j.clon.2017.10.013

M3 - Editorial

AN - SCOPUS:85034456360

VL - 30

SP - 1

EP - 4

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 1

ER -